United Kingdom (UK)
Recombinant monoclonal antibody to Factor VIII A2 domain. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the human B cell clone BOIIB2.
UniProt Accession Number of Target Protein: P00451
Alternative Name(s) of Target: AHF; FVIII; A2 domain; Factor 8; anti-hemophilic factor; Coagulation factor VIII; procoagulant component
Immunogen: The original antibody was generated from the peripheral blood lymphocytes obtained from a hemophilia patient.
Specificity: This antibody binds the A2 domain of the human factor VIII, a glycoprotein involved in blood coagulation. Factor VIII acts as a cofactor for factor IXa which converts factor X to the activated form Xa in the presence of calcium and phospholipids. Defects in the F8 gene, which encodes Factor VIII, result in the coagulation disorder hemophilia A.
Application Notes: The binding specificity and epitope characterization of this antibody was determined using ELISA. The ability of this antibody inhibit factor VIII function in vitro was studied using a chromogenic functional assay. It was reported that this antibody inhibited the conversion of factor X to factor Xa at concentration of 0.1 μg/ml. It was found that this antibody inhibits thrombin production using both the intrinsic and extrinsic pathway of coagulation (US20080206254).
Antibody first published in: PMID: